Alberto Jose Cabrera Quintero

Alberto Jose Cabrera Quintero

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015
Verified
Journal Article
Closed access
IMIrma B Mitre-Aguilar
Irma B Mitre-Aguilar
AQAlberto Jose Cabrera Quintero
Alberto Jose Cabrera Quintero
ADALEJANDRO ZENTELLA DEHESA
ALEJANDRO ZENTELLA DEHESA

27 June 2020 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
MGMontserrat Guadalupe Garza-Reyes
Montserrat Guadalupe Garza-Reyes
MMMónica Daniela Mora-Ruíz
Mónica Daniela Mora-Ruíz
LCLuis Chávez
Luis Chávez
AMAlejandra Madrid-Miller
Alejandra Madrid-Miller
AQAlberto Jose Cabrera Quintero
Alberto Jose Cabrera Quintero
ACAlicia Contreras-Rodríguez
Alicia Contreras-Rodríguez
Interleukin- (IL-) 17 is increased in acute myocardial infarction (AMI) and plays a key role in inflammatory diseases through its involvement in the activation of leukocytes. Here, we describe for the first time the effect of IL-17 in the migration and activation of monocyte subsets in patients during ST-segment elevation myocardial infarction (STEMI) and post-STEMI. We analyzed the circulating levels of IL-17 in patient plasma. A gradual increase in IL-17 was found in STEMI and post-STEMI patients. Additionally, IL-17 had a powerful effect on the recruitment of CD14++CD16+/CD14+CD16++monocytes derived from patients post-STEMI compared with the monocytes from patients with STEMI, suggesting that IL-17 recruits monocytes with inflammatory activity post-STEMI. Furthermore, IL-17 increased the expression of TLR4 on CD14+CD16-and CD14++CD16+/CD14+CD16++monocytes post-STEMI and might enhance the response to danger-associated molecular patterns post-STEMI. Moreover, IL-17 induced secretion of IL-6 from CD14++CD16−and CD14++CD16+/CD14+CD16++monocytes both in STEMI and in post-STEMI, which indicates that IL-17 has an effect on the secretion of proinflammatory cytokines from monocytes during STEMI and post-STEMI. Overall, we demonstrate that in STEMI and post-STEMI, IL-17 is increased and induces the migration and activation of monocyte subsets, possibly contributing to the inflammatory response through TLR4 and IL-6 secretion.

15 April 2019 in BMC Cancer
Verified
Journal Article
Open access
PDF file
IAIrma Beatriz Mitre Aguilar
Irma Beatriz Mitre Aguilar
TBTonatiuh Barrios-Garcia
Tonatiuh Barrios-Garcia
VRVictor Ruiz
Victor Ruiz
AQAlberto Jose Cabrera Quintero
Alberto Jose Cabrera Quintero
NMNancy R. Mejía-Domínguez
Nancy R. Mejía-Domínguez
ADALEJANDRO ZENTELLA DEHESA
ALEJANDRO ZENTELLA DEHESA
Glucocorticoid receptor (GR) activation has been associated with breast cancer cell survival in vitro. Glucocorticoid (GC)-dependent protection against tumor necrosis factor (TNF)-induced cell death has been well characterized in MCF7 luminal A breast cancer cells. The GR activates a variety of protective mechanisms, such as inhibitors of apoptosis proteins (IAPs). However, the relative contribution of the GR-dependent expression of IAPs in the protection of cell death has not, to our knowledge, been evaluated. MCF7 cells were used for all experiments. GR was activated with cortisol (CORT) or dexamethasone (DEX) and inhibited with mifepristone (RU486). Cell viability was determined in real-time with the xCELLigence™ RTCA System and at specific endpoints using crystal violet stain. The mRNA levels of the eight members of the IAP family were measured by qRT-PCR. The protein levels of GR, PR, ERα, HER2, PARP1, c-IAP1 and XIAP were evaluated by Western blot analysis. The knockdown of c-IAP1 and XIAP was accomplished via transient transfection with specific siRNAs. GR activation was verified by a gene reporter assay. Via the cBioportal interphase we queried the mRNA levels of GR and IAPs in breast cancer tumors. RU486 significantly inhibited the anti-cytotoxic effect of both GCs. PARP1 processing was diminished in the presence of both GCs. The combined treatments of GCs + TNF increased the relative mRNA levels of Survivin>c-IAP1 > NAIP>Apollon>XIAP>Ts-IAP > ML-IAP > c-IAP2. Additionally, GR mRNA content increased with the combined treatments of GCs + TNF. Sustained levels of the proteins c-IAP1 and XIAP were observed after 48 h of the combined treatments with GCs + TNF. With c-IAP1 and XIAP gene silencing, the GC-mediated protection was diminished. In the breast tumor samples, the GR mRNA was coexpressed with Apollon and XIAP with a Pearson coefficient greater than 0.3. The effect of GCs against TNF-mediated cytotoxicity involves increased mRNA expression and sustained protein levels of c-IAP1 and XIAP. The antagonist effects of RU486 and the qRT-PCR results also suggest the role of the GR in this process. This finding may have clinical implications because the GR and IAPs are expressed in breast tumor samples.

12 April 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Laura Cecilia Flores-GarcíaLaura Cecilia Flores-García
Laura Cecilia Flores-García
JVJosé L. Ventura-Gallegos
José L. Ventura-Gallegos
SRSandra L. Romero-Córdoba
Sandra L. Romero-Córdoba
AHAlfredo J. Hernández-Juárez
Alfredo J. Hernández-Juárez
MNMaría A. Naranjo-Meneses
María A. Naranjo-Meneses
ADALEJANDRO ZENTELLA DEHESA
ALEJANDRO ZENTELLA DEHESA
Obesity is associated with an increased incidence and aggressiveness of breast cancer and is estimated to increment the development of this tumor by 50 to 86%. These associations are driven, in part, by changes in the serum molecules. Epidemiological studies have reported that Metformin reduces the incidence of obesity-associated cancer, probably by regulating the metabolic state. In this study, we evaluated in a breast cancer in-vitro model the activation of the IR-β/Akt/p70S6K pathway by exposure to human sera with different metabolic and hormonal characteristics. Furthermore, we evaluated the effect of brief Metformin treatment on sera of obese postmenopausal women and its impact on Akt and NF-κB activation. We demonstrated that MCF-7 cells represent a robust cellular model to differentiate Akt pathway activation influenced by the stimulation with sera from obese women, resulting in increased cell viability rates compared to cells stimulated with sera from normal-weight women. In particular, stimulation with sera from postmenopausal obese women showed an increase in the phosphorylation of IR-β and Akt proteins. These effects were reversed after exposure of MCF-7 cells to sera from postmenopausal obese women with insulin resistance with Metformin treatment. Whereas sera from women without insulin resistance affected NF-κB regulation. We further demonstrated that sera from post-Metformin obese women induced an increase in p38 phosphorylation, independent of insulin resistance. Our results suggest a possible mechanism in which obesity-mediated serum molecules could enhance the development of luminal A-breast cancer by increasing Akt activation. Further, we provided evidence that the phenomenon was reversed by Metformin treatment in a subgroup of women.

1 January 2018
Verified
Journal Article
Closed access
AEAlma R. Escalona-Guzman
Alma R. Escalona-Guzman
RHRicardo Hernandez-Garcia
Ricardo Hernandez-Garcia
FVFelipe Vadillo-Ortega
Felipe Vadillo-Ortega
RLRebeca Lopez-Marure
Rebeca Lopez-Marure
JMJanini Mejia-Rangel
Janini Mejia-Rangel
ADALEJANDRO ZENTELLA DEHESA
ALEJANDRO ZENTELLA DEHESA

7 October 2026 in Future Microbiology
Verified
Journal Article
Closed access
JSJuan Carlos Gutiérrez Santana
Juan Carlos Gutiérrez Santana
AQAlberto Jose Cabrera Quintero
Alberto Jose Cabrera Quintero
FSFrancisco Cuevas Schacht
Francisco Cuevas Schacht
ADALEJANDRO ZENTELLA DEHESA
ALEJANDRO ZENTELLA DEHESA
VCVictor R. Coria-Jiménez Coria-Jiménez
Victor R. Coria-Jiménez Coria-Jiménez